New antivenom could save lives in remote areas
NCT ID NCT07659002
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 600 people in Ethiopia who receive a new type of snakebite antivenom called Premium-PANAF. The antivenom is freeze-dried, so it does not need refrigeration, making it easier to use in remote clinics. Researchers want to see if it safely stops the effects of snake venom and helps patients recover.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Premium-PANAF polyvalent snake antivenom
- What this could lead to
- If this antivenom proves safe and effective, it could become a standard treatment for snakebites in resource-limited areas, saving many lives.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. Allergic reactions or lack of effectiveness are possible risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SNAKE ENVENOMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abdurafi Health Center
RECRUITINGĀbderafī, Amhara, Ethiopia
More trials for these conditions
Other studies related to the condition(s) this trial covers.